Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conivaptan in Euvolemic or Hypervolemic Hyponatremia
NCT00492037Phase 3Completed
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Jan 2000
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in hyponatremia comparing Conivaptan with Placebo (2 arms). Primary endpoints: Change in serum sodium from Baseline at 5 days and Safety of each dosing regimen at 5 days. Started Jan 2000; status: completed.
02
Drugs
conivaptan
03
Conditions
hyponatremia
Beyond the preview
Go deeper on NCT00492037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492037.